Research location

Syracuse

New York, United States

Published trials839

Site observations999

Linked trials published839

Page1 / 17

Research activity in Syracuse

New York, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 839 trials and 999 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Syracuse

839 linked trials · page 1 of 17

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After TreatmentNCT07293247 · 2026-10-14 · 2 site observations

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)NCT07743190 · 2026-10-01 · 1 site observation

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideNCT07668414 · 2026-09-22 · 1 site observation

A Study of JNJ-101556143 in Participants With Metastatic Prostate CancerNCT07832292 · 2026-09-16 · 1 site observation

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedNCT07650916 · 2026-06-25 · 1 site observation

Evaluation of the Fully Closed Loop Omnipod® System in Type 2 DiabetesNCT07521475 · 2026-04-30 · 1 site observation

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 · 2026-01-08 · 1 site observation

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerNCT06686771 · 2025-12-16 · 1 site observation

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · 2025-10-24 · 1 site observation

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart FailureNCT07069738 · 2025-10-22 · 1 site observation

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · 2025-09-11 · 1 site observation

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationNCT06952803 · 2025-08-06 · 1 site observation

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseNCT06976216 · 2025-07-14 · 1 site observation

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCNCT06855277 · 2025-07-01 · 1 site observation

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseaseNCT06808984 · 2025-06-09 · 1 site observation

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)NCT06878261 · 2025-03-25 · 1 site observation

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514 · 2025-02-27 · 1 site observation

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted TherapyNCT06780670 · 2025-02-27 · 1 site observation

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate CancerNCT06800313 · 2025-02-06 · 1 site observation

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsNCT06418204 · 2025-01-30 · 2 site observations

Acceptance and Commitment Therapy for HIV+ Hazardous DrinkersNCT06648629 · 2025-01-22 · 1 site observation

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)NCT06739122 · 2025-01-10 · 1 site observation

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)NCT06733935 · 2024-11-04 · 1 site observation

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney DiseaseNCT06217302 · 2024-10-31 · 1 site observation

A Study of Lower Radiotherapy Dose to Treat Children With CNS GerminomaNCT06368817 · 2024-10-22 · 1 site observation

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21 · 1 site observation

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · 2024-10-07 · 1 site observation

Registry for Stage 2 Type 1 DiabetesNCT06481904 · 2024-09-27 · 1 site observation

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)NCT06585787 · 2024-09-26 · 2 site observations

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialNCT06096844 · 2024-07-19 · 2 site observations

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277 · 2024-06-03 · 1 site observation

Effects of HIIT vs. TRE on Type 2 Diabetes RiskNCT07215533 · 2024-03-15 · 1 site observation

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.NCT05939414 · 2024-03-12 · 1 site observation

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18 · 1 site observation

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerNCT05946213 · 2023-12-14 · 2 site observations

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27 · 2 site observations

ACP-204 in Adults With Alzheimer's Disease PsychosisNCT06159673 · 2023-11-14 · 1 site observation

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 · 2023-10-26 · 1 site observation

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-TNCT06134232 · 2023-10-02 · 1 site observation

HIIT Effects on Cardiometabolic HealthNCT05838950 · 2023-09-29 · 1 site observation

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12 · 1 site observation

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)NCT05980949 · 2023-07-11 · 2 site observations

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07 · 1 site observation

Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric DisordersNCT05656469 · 2023-02-23 · 1 site observation

Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVRNCT05459233 · 2023-01-11 · 1 site observation

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation

[18F]PI-2620 Phase 3 Histopathological StudyNCT05641688 · 2022-12-01 · 1 site observation

Pimavanserin vs. Quetiapine for Treatment of Parkinson's PsychosisNCT04373317 · 2022-10-24 · 1 site observation

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaNCT05235165 · 2022-04-01 · 1 site observation

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483 · 2021-12-14 · 1 site observation

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.